Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…
Deciphera Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…
Zai Lab Limited Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $172.5 million initial public offering by Zai Lab Limited of 9,583,333 American…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…
Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…
Akcea Therapeutics Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…
Mersana Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…